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Abstract
Background: Fahr’s disease is rare a neurodegenerative idiopathic condition characterized by symmetric and
bilateral calcifications of basal ganglia, usually associated with progressive neuropsychiatric dysfunctions and
movement disorders. The term “Fahr’s syndrome” is used in presence of calcifications secondary to a specific
cause, but the variability of etiology, pathogenesis, and clinical picture underlying this condition have raised the
question of the real existence of a syndrome. Several classifications based on the etiology, the location of brain
calcifications and the clinical presentation have been proposed. Here we describe seven clinical cases of basal
ganglia calcifications, in order to search for pathognomonic features and correlations between clinical picture
and imaging findings.
Cases presentation: The patients came to our attention for different reasons (most of them for memory/behavior
disturbances); all underwent neuro-psychologic evaluation and neuro-imaging. All patients showed variable degrees of
deterioration in cognitive function; anxiety and depression were frequent too, and resistant to treatment in all cases.
Less frequent, but severe if present, were psychotic symptoms, with different grade of structure and emotional
involvement, and always resistant to treatment. We observed only few cases of extrapyramidal disorders related
to the disease itself; anyway, mild extrapyramidal syndrome occurred quite frequently after treatment with antipsychotics.
Conclusion: Based on these findings we discourage the use of the term “Fahr’s syndrome”, and suggest to refer
to Idiopathic or Secondary basal ganglia calcification. Unlike early onset forms (idiopathic or inherited), the clinical
presentation of late onset form and Secondary basal ganglia calcification seems to be really heterogeneous.
Case–control studies are necessary to determine the actual significance of basal ganglia calcification in the adult
population and in the elderly, in cognitive, physical and emotional terms.
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Background
Fahr’s disease, Bilateral striopallidodentate calcinosis [1],
and Idiopathic basal ganglia calcification [2] are three of
the more than 30 names used to identify a rare neurode-
generative condition characterized by the presence of bi-
lateral calcification of the basal ganglia and other parts
of the brain [3]. This condition has a wide range of pos-
sible clinical manifestations, usually marked by neuro-
psychiatric symptoms (i.e. dementia, schizophrenia-like
psychosis, mood disorders), and extrapiramidal movement
disorders [3]. Fahr was the first author who, despite a few
previous case-reports by others [4, 5], described in 1930 the
case of a demented patient with movement disturbances,
whose autopsy revealed vascular non atherosclerotic calcifi-
cations in centrum semiovale and striatum [6].
For years, the terms Fahr’s disease and Fahr’s syndrome
have been used indistinctly to identify different clinical
conditions characterized by basal ganglia calcification.
Nowadays, several authors use the term syndrome refer-
ring to clinical cases, symptomatic or not, in which a
specific cause can be identified at the basis of brain cal-
cification [7]. Nevertheless, there is no agreement about
the use of the term “Fahr’s syndrome”, since, under this
name, are grouped a very wide range of conditions,
with different etiologies, pathogeneses, and different
clinical phenotypes, raising the question of the real exist-
ence of such a syndrome. In fact, a study conducted in
2007 found that among 1569 healthy subjects, 0.8 % pre-
sented basal ganglia calcifications at CT scan, apparently
without any symptoms, thus inducing the authors to con-
sider them intracranial “physiological” calcifications [8].
More recently, irrespective of the etiology, Manyam
proposed a classification based on the anatomical site
in which calcium and other minerals depose, including
1. striopallidodentate calcinosis, 2. bilateral striopallidal
(basal ganglia) calcinosis, and 3. bilateral cerebellar cal-
cification [3]. In this paper we report seven consecutive
cases of patients with basal ganglia calcification detected
from a series of 750 patients referring to our Clinic for the
study of Cognitive Diseases or to our Internal Medicine
Ward from January 2003 to December 2013. Our purpose
was, in a group of patients with non-genetic forms of
basal ganglia calcinosis, to evaluate whether a clinical
picture corresponding to neuroimaging could be de-
tected and, consequently, whether the use of the term
“syndrome” may be correct.
Case presentation
Case 1
M.G., a 73 year old man, came to our attention after the
instruction of mandatory medical treatment, disposed to
the police after reports of inadequate behavior. After re-
pulsing his wife and daughter, five years before, he had
been living alone, in a state of total neglect. His medical
history was positive for type 2 diabetes, and a previous
transient ischemic attack. No family history of neurologic
nor psychiatric disturbances was reported. The physical
examination revealed only poor self-care and bradykinesia.
The findings at neuropsychological testing are summa-
rized in Table 1.
Blood tests, comprehensive of calcium and phosphate,
were normal. Computed Tomography (CT) scan (Fig. 1-a)
and Magnetic Resonance Imaging (MRI) findings are
summarized in Table 1. An antipsychotic treatment was
started (quetiapine up to 200 mg/day) with poor re-
sponse; after discharge behavior disorders recurred,
inducing forced hospitalization in a nursing home. He
displayed extrapyramidal symptoms, strong structured
delusions, and worsening of dementia.
Case 2
D.C., a 37 years old man, came to our attention for psy-
chiatric evaluation to assess his capacity of discernment
and his social dangerousness, after receiving a complaint
for theft. The only anamnestic element was a head injury
occurred 11 years before. After this trauma, his personality
had changed with aggressiveness, recurrent migraine with
auditory/olfactory hallucinations. A treatment with halo-
peridol had been tried, suspended because of scarce effect
on psychotic disturbances and appearance of extrapyra-
midal symptoms. An extensive bilateral calcification of
globus pallidus was revealed by CT scan. The findings
of psychiatric examination are summarized in Table 1.
Case 3
E.F., a 54 years old man, came to our observation for
weight loss, weakness, and hyporexia. He had a psychi-
atric history of “somatoform autonomic dysfunction”,
and had been followed by local Psychiatric Service
during the previous years, and treated with selective
serotonin reuptake inhibitors (SSRI) at maximum dose
with inadequate results. His anamnesis was positive for
coronary heart disease, hypertension, dyslipidemia,
hyper-omocysteinemia, and monoclonal gammopathy
of undetermined significance. Except for the rapid de-
crease in body weight, the physical and neurologic
examination was unremarkable, as well as blood exams,
abdominal ultrasound, and chest X-rays. Gastroscopy
showed the presence of bulbar erosive duodenitis. The
results of his psychiatric evaluation are summarized in
Table 1. A CT scan revealed the presence of bilateral
hyperdense calcium deposits in globus pallidus, and
slight dilatation of the pericerebellar fluid space because
of atrophy (Fig. 1-b-). A treatment with sertraline up
to 150 mg/day, together with aripiprazole (15 mg/day)
was started, with slight improvement in mood and
clinical conditions.
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Table 1 Principal characteristics of the seven subjects with Fahr’s disease
Case Gender Age Diagnosis Risk factors Classification by
Manyam (and other
neuroimaging findings)
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B.S., a 48 years old woman, came to our attention sent
by her psychiatrist for a neuro-psycological evaluation.
She had a family history of vascular dementia, and her
medical history was positive for hypothyroidism, obesity,
dyslipidemia, and hypertensive cardiopathy. After a car
accident with brain injury occurred 10 years before, she
had suffered from anxious-depressive syndrome; some
years later, a second car accident with brain trauma oc-
curred. She was treated with venlafaxine and quetiapine,
with poor response. Physical and neurologic examination
were unremarkable, except for mild frontal liberation
signs. Blood test showed hyperparathyroidism (Parathyroid
hormone: 83 pg/ml; normal range: 12–65 pg/ml) associated
with hypovitaminosis D (vitamin D: 10.8 ng/ml; normal
range: 20–120 ng/ml); serum calcium was within normal
values (2.55 mmol/l; normal range: 2.15–2.55 mmol/l). A
thyroid ultrasound examination was unremarkable,
parathyroids were not visible. Brain CT scan (Fig. 1-c) and
neuropsychological evaluation results are shown in Table 1.
Case 5
B.M., a 63 years old woman, was admitted to our Day Hos-
pital after two episodes of syncope. She denied seizures,
bite, and sphincter relaxation, but reported tinnitus and
gait instability lasting two months. For this reason she had
already undergone several examinations showing mild ath-
erosclerotic carotid disease, a phenotype II-b dyslipidemia,
and a deficit of Vitamin D without calcium, phosphorus or
parathyroid hormone alterations. Her anamnesis was posi-
tive for hypertension, thyroid nodules, smoking habit. She
had an high level of education (university degree) and a
family history of depression and dementia. Physical and
neurological examinations were normal except for ortho-
static hypotension. The findings at cerebral MRI and CT
scan, and results from neuropsychological tests are sum-
marized in Table 1 and shown in Fig. 1-d.
Case 6
M.M., a 73 years old woman was referred to our clinic for





Fig. 1 CT scan imaging of Cases 1,3,4 and 5. a Case 1. CT scans: extensive bilateral calcification of pallidus nuclei of basal ganglia and dentate
nuclei of cerebellum; Hypodense malacic aspect in left frontal lobe. b Case 3. CT scans: mineral hyperdense deposits in bilateral pallidus nuclei
without other area of altered density. Small enlargement, age-related, of frontal cerebral sulci due to atrophy. c Case 4. CT scans: hyperdense
simmetric calcific deposits in pallidus nuclei and caudate nuclei of both sides. d Case 5. CT scans: hyperdense bilateral calcific deposits in the head
of caudate nuclei, putamen and pallidus nuclei
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visual hallucinations, and sleep disorders. At the time
of first visit she was still totally independent in basic,
and partially in instrumental activities of daily living
(score 18/19). Her anamnesis was positive for hyperten-
sion, COPD (Chronic Obstructive Pulmonary Disease),
and major depression. Her physical examination showed
mild frontal liberation and extrapyramidal signs (see
Table 1). Blood tests revealed increased parathyroid
hormone with normal calcium levels. Brain CT scan
showed important bilateral calcification of globus palli-
dus. Citalopram (20 mg/day), risperidone (2 mg/day),
and oxazepam were prescribed. On follow-up her memory
and movement disturbances gradually worsened with
development of psychotic symptoms (see Table 1), and
a second CT scan revealed the worsening of known cal-
cifications and development of degenerative/vascular
encephalopathy (see Table 1). Quetiapine (100 mg/day)
and promazine (200 mg/day) were prescribed in place
of risperidone, with partial response. She progressively
lost her independence until refusing of feeding on, and
died at the age of 81.
Case 7
C.L., a 82 years old woman was admitted to our ward
for a lipothymia. Her anamnesis was positive for hyper-
tension, carotid atherosclerosis, previous stroke, and fre-
quent falls in the last 5 years. Her familiar history was
positive for dementia. Neurological examination revealed
both pyramidal and extrapyramidal signs (see Table 1).
At neurologic evaluations cognitive impairment, depres-
sive symptoms, and hallucinations emerged. Blood test
revealed vitamin D deficiency, with increased parathy-
roid hormone and hypercalcemia, and a brain CT scan
showed diffuse atrophy, and basal ganglia calcification. Ser-
traline, nimodipine, and vitamin D supplementation were
started, with poor response. The progressive worsening of
hypertonia, resistant to L-dopa treatment, caused several
further falls, with many bone fractures. She progressively
loss independency, was institutionalized, and developed
aggressive behaviour responsive to promazine.
Revision of literature
Epidemiology
The frequency of incidental finding of basal ganglia cal-
cification during CT scan raised from an incidence of
0.24–0.75 % during the eighties [9–12], until 12.5 % in
two thousands [13, 14]. The reason of this increase de-
pends on one side on the wide spread of CT-scan, and,
on the other side, on larger new diagnostic criterions
(from minimal monolateral calcification isolated to glo-
bus pallidus to massive bilateral calcification [3]. Fahr’s
disease is considered a rare disorder, even if its real
prevalence is still unknown. The epidemiology of this
disease is so hard to be obtained for several reasons:
firstly for the plethora of names used indistinctly to
identify different conditions, secondly for the complexity
of diagnosis with a wide spectrum of clinical manifesta-
tions (from asymptomatic people, to severe cognitive
and movement disturbances), finally because the clinical
manifestations are reported in literature mainly as case
reports or small series. For example, applying uniform
criteria to 61 cases of literature and 38 cases seen in a
registry, Manyam found that less than 70 % of subjects
were symptomatic [15]. There are no data indicating the
mean age of onset of the disease, nor suggesting a gen-
der prevalence, even if in the cited work by Manyam the
male–female ratio was 2:1 [15].
Etiology and histopathology
Considering the etiology, bilateral striopallidodentate
calcinosis can be subdivided into four forms, with first to
third belonging to Fahr’s disease, that means lacking of
secondary causes [1]: 1. Autosomal dominant; 2. Familial;
3. Sporadic; 4. Secondary. The autosomal dominant form
involves different people in the same parental line (parents
or offsprings of the proband), and seems associated mainly
to chromosome locus 14q48 mutation (IBCG1) [16–19].
Familial form is diagnosed when many members of the
same family are affected, but this can be accounted for by
chance, and there are not the characteristics to consider it
a genetic form [3]. Fahr’s disease is sporadic when only
one person of a family is affected; of course, the lack of
symptoms in other family members is not enough to con-
sider sporadic a case, but adequate neuroimaging studies
should rule out brain calcifications. It must be under-
lined that a certain degree of calcification of basal
ganglia can be considered “physiological” with aging,
over 50 years [20].
Secondary forms, called Fahr’s syndrome by some au-
thors, have been associated with several diseases, including:
A) Abnormalities in calcium and phosphate metabolism,
mainly hyper- [21, 22], hypo- [23, 24] and pseudo-
hypoparathyroidism [25, 26]; B) Brain infections, such
as Acquired Immune Deficiency Syndrome (AIDS) [27],
Epstein–Barr virus [28], and other meningoencephalitis
[29]; C) tumors (mainly angiomas and cerebral gliomas)
[30, 31]; D) systemic lupus erythematosus [32, 33]; E)
previous head injuries [34]. Calcium deposition involves
basal ganglia, thalami, dentate nuclei of cerebellum,
and occasionally cortical and sub-cortical frontal, par-
ietal and occipital regions connecting associative cortex
to basal ganglia and thalami [35]. The involvement of
such a complex system explains the possible presence
of movement, cognitive, and behavioral/emotional disor-
ders in affected patients [35]. Histological and chemical
studied demonstrated that several minerals are involved in
the disease, like iron, magnesium, aluminum, and zinc [3],
but the exact pathophysiological pathway is still unknown.
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We can argue, firstly, that the anatomy of the local arterial
system could determine a low blood flow, leading to a re-
duction of glucose metabolism [36]. Secondly, there could
be a slowly progressive metabolic and inflammatory modi-
fications that lead to calcium deposition [37]. Differently
from atherosclerotic lesions, the intima is spared [38] and
the deposits mainly affect adventitia and basal membrane
of the small vessels and the perivascular spaces [39]. Neur-
onal degeneration and gliosis in the surrounding areas
firstly involve astrocytes [40], initially causing hypertrophy
and hyperplasia, and finely leading to necrosis [41]. The
affected areas are characterized by the deposition of
muchopolysaccharides and proteins, followed by cal-
cium and phosphorus in form of hydroxyapatite [42]. The
extravascular deposition of an acid mucopolysaccharide-
alkalic protein complex was suggested as a mechanism for
the secondary accumulation of calcium, with vascular
membrane abnormalities responsible for the leakage of
plasma-derived fluid as suggested by MRI studies [38].
Furthermore, calcium phosphate deposition would be fa-
cilitated by the high concentration of iron and alkaline
phosphatase in these areas [43]. Finally, basal ganglia are
known to be the target for many other mineral and
non-mineral deposits, such as bilirubin in the newborn,
methyl-phenyl-tetrahydropyridine (MPTP) and carbon
monoxide in poisoning [3], maybe indicating an intrin-
sic vulnerability of this system.
Clinical features
The clinical presentation of the disease is really variable
with a wide range of clinical presentations, from the
completely asymptomatic subject to the patient with
severe extrapyramidal and neuropsychiatric disorders.
As already said, Manyam reported symptomatic subjects
as being about 68 % in a series of 99 patients [15]; in symp-
tomatic patients, the most commonly reported symptoms
were movement disorders (55 %), like Parkinsonism,
chorea, tremors, dystonia, athetosis, oro-facial diskinesia),
followed by cognitive impairment (39 %), speech disorder
(36 %), cerebellar impairment (36 %), and psychiatric
symptoms (31 %). Relatively rare were pyramidal signs,
gait disorders, sensory changes, and pain [15]. No dif-
ferences in clinical presentation were found comparing
secondary forms and Fahr’s disease. Similarly, no spe-
cific clinical patterns were found to be associated with
the localization of calcium deposits, with similar clin-
ical features in striopallidodentate, striopallidal, and
dentate calcinosis. The only aspect significantly influen-
cing the clinical features of Fahr’s disease seems to be
the age of onset (probably because of a different and
yet completely unknown etiology). Based on this, three
different clinical patterns are distinguished [44]: 1) a
very rare infantile form; 2) an early onset type, developing
symptoms in the thirties, and mainly characterized by
schizophrenia-like psychosis, with a lower role of move-
ment disorders; 3) a late onset type, with symptoms onset
in the fifties, whose typical features are dementia and
movement disorders (Table 2). Movement disorders usu-
ally present early in the late onset form (even if sometimes
late development of movement disorders have been re-
ported), while they appear late in the early onset form,
probably when progressive neurodegeneration exceeds a
certain threshold. Dementia, with the classical characteris-
tics of the primary sub-cortical types [45–47], is typical of
Table 2 Principal clinical features of Fahr’s disease
Fahr’s disease
Early onset Late onset
Cognitive impairment/dementia A cortical dementia may develop in
advanced stages
Usually starts with a subcortical dementia
Psychotic disorders Organic psychosis (basal ganglia calcification);
delusion has syndromic pervasiveness behavioral,
is moderately structured and organized, has low
emotional participation, varied content.
Abnormalities of perception are rare.
Organic psychosis (dementia): delusion is poorly
structured and organized, override the contents of
jealousy, poisoning, and persecution. Abnormalities
of perception are frequent.
Mood disorders May be associated to psychotic symptoms.
Depressive disorders are prevalent towards
maniacal ones.
Always associated with cognitive impairment, may
precede symptoms as prodromes. Prevailing
depression, irritability, hyper-emotionality, apathy
Anxiety disorders Possible association between Fahr’s disease
and obsessive-compulsive disorder.
Possible association between Fahr’s disease and
obsessive-compulsive disorder. They can also be
associated to cognitive impairment
Other neuro psychiatric/cognitive
disorders
Possible attention’s disorders. Progressive alteration of cognitive functions
(attention, language, memory, constructive
abilities, etc.)
Extrapyramidal movement disorders In advanced stages of the disease. May be present since the onset.
Response to therapy Poor sensibility to neuroleptic treatment;
high susceptibility to side effects.
Poor response to any type of symptomatic therapy.
Frequent side effects.
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the late onset type, but in younger patients a secondary
evolution to dementia has been reported too. The patho-
genesis of cognitive impairment is related to the destruc-
tion of connection between basal ganglia and cortex, also
leading to fronto-temporal atrophy, formation of cortical
neurofibrillar aggregates and loss of neurons, both in cor-
tex and basal ganglia [45]. Psychotic symptoms are charac-
teristic of the early onset form, and an association was
hypothesized between the severity of clinical expression
and the extension of calcifications [48]. This form was
considered by DSM-IV (fourth version of the Diagnostic
and Statistical Manual of Mental Disorders) one of the
“psychotic disorders due to a general medical condition”,
and as other organic psychosis is characterized mainly by
hallucinations and delirium, but also mood and attention
may be affected. Psychotic symptoms include auditory,
visual and olfactory hallucinations, ideas of reference and
persecutory delusions [45, 46, 49, 50]. Typically, psychiatric
symptoms poorly respond to antipsychotic treatment, and
an increase in susceptibility to adverse reactions to these
therapies was documented [44]. Finally, in both clinical
forms of the disease, other neuropsychiatric symptoms
may occur, such as mood disorders (mainly depressive
symptoms) and anxiety disorders.
Prognosis
Fahr’s disease is characterized by a progressive and ex-
tremely variable course; for this reason, the prognosis is
really variable and hard to predict. The neurodegenera-
tive evolution of the disease was confirmed in two recent
studies, in which brain CT scans demonstrated the de-
velopment of cerebral atrophy in some affected patients
[15, 51].
Diagnosis
The diagnosis of Fahr’s disease is based on the presence
of brain calcification on CT scan, together with the clinical
manifestations, in absence of demonstrated alterations in
calcium and phosphate serum levels and metabolism.
However, because of the frequency of asymptomatic pa-
tients, the incidental diagnosis in patients undergoing
brain CT scan for other reasons is possible. When par-
kinsonism is associated to dementia and cerebellar
signs, obtaining a CT scan might be helpful [3]; when
brain imaging is positive for bilateral striopallidodentate
calcification, obtaining serum calcium and parathor-
mone levels should help differentiating Fahr’s disease
from hypoparathiroidism, which is the major differen-
tial diagnosis [3], leading to the diagnosis of secondary
basal ganglia calcification. As regards secondary forms,
the diagnosis is made, independently of the presence of
symptoms, when cerebral calcifications are present at
brain imaging, and a specific factor able to cause them
is demonstrated. Among the neuroradiologic exams,
brain CT is more sensitive than traditional MRI in the
detection of calcium deposits [52], but the recently intro-
duced SWI (Susceptibility-weighted imaging) MRI seems
to be more sensitive for early changes [53, 54]; another
useful tool is the 99mTehexamethyl-propylenamine oxime
(99mTc-HMPAO) single proton emission computed tom-
ography (SPECT)[55], revealing markedly decreased per-
fusion involving the basal ganglia bilaterally and cerebral
cortices [56].
No marked alterations are found at neurophysiologic
studies in Fahr’s disease patients: excluding the possible
finding of minor abnormalities at brainstem auditory-
evoked potentials, all other neurophysiologic exams give
completely normal results [3]. Finally, decreased cere-
brospinal fluid levels of calcium were detected in one
study [57], but a confirmation is needed yet.
Therapy
There is no therapy able to limit the progression of basal
ganglia calcification in patients with Fahr’s disease.
Moreover, despite a specific approach to all etiological
identified factors, no improvement was demonstrated
in secondary forms. In this context, at present time
management and treatment strategies mainly focus on
symptomatic relief, and are strictly related with the
clinical features.
Conclusions
In the present work we describe the clinical presentation
of seven subjects with basal ganglia calcification. By
comparing these clinical cases with current Literature
we observed that actual studies don’t allow conclusions
about real clinical features of basal ganglia calcification,
in relation to qualitative and methodological limitations.
The only exception is represented by inherited Fahr’s
disease, in which the early calcium deposition in nucleus
pallidus and striatum is inevitably related to severe, al-
though heterogeneous, clinical manifestations. Moreover,
it must be pointed out that the very few anatomical
pathology studies show a late neuronal involvement;
therefore, it is not possible to relate in any way the mor-
phological findings obtained by CT scan with the real
impairment of the anatomic pathways concerned. Several
observations can be made considering the seven, hetero-
geneous, presented cases.
Patient of Case 1, was affected by strio-pallido-dentate
calcinosis. This is probably a case of Fahr’s disease with
severe primitive calcifications, even if a form secondary
to cerebrovascular disease cannot be excluded. However,
the clinical picture favors the hypothesis of Late onset
Fahr’s disease, since well-structured delusions with emo-
tional involvement are very rare in vascular dementia
[58]. Extrapiramidal disorders developed two years
after the first observation: they might represent late
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symptoms of the disease or side effect of antipsychotic
treatment. The disappointing response to this treat-
ment, and the possible development of side effects, are
in favour of Fahr’s disease [44].
Case 2 was affected by strio-pallidal calcinosis [3],
probably this was a case of Secondary BGC (Basal Gan-
glia Calcification) due to the previous brain injury. As
reported for early onset forms, the predominant symp-
tom was the psychotic disorder. Also mild cognitive im-
pairment is a typical symptom of BGC, even if in early
onset type it usually appears later. Unfortunately, no in-
formation about the neurologic examination before
starting antipsychotic therapy was available; however at
the time of evaluation the patient was amimic: in lack of
other elements this could suggest a Parkinsonism. Finally,
the unsuccessful response and hypersensitivity to anti-
psychotic therapy supports SBCG diagnosis [44].
Case 3 presented with a strio-pallidal calcinosis [3]
too, but the later beginning of the symptoms configures
a late onset idiopathic form, although we don’t actually
know the duration of the psychiatric disturbance before
the patient was taken in charge. The preponderant
symptom was the anxious-depressive syndrome resist-
ant to drugs. The observation of memory deficit sug-
gests the presence of cognitive impairment, even if a
complete neuropsychological evaluation was not avail-
able. However, the relatively lower impact of cognitive
deficit compared with mood disorder is typical of the
early onset forms. Besides basal ganglia calcification,
the mild atrophy showed at CT scan could explain, at
least in part, the cognitive deficits.
Case 4 presented a strio-pallidal calcinosis [3], in this
case due to a probable secondary BGC. A mood disorder
was the prevalent symptom, even if a mild cognitive
impairment was also detected. Two probable etiologic
elements must be considered: severe hypovitaminosis
D with secondary hyperparathyroidism and brain in-
jury. Alteration in calcium/D vitamin metabolism can
be at the basis of BGC [21, 22], but symptoms develop
only after the brain injury, which seems to act as a
trigger in this case. Probably, the brain injuries accele-
rated the evolution of the pathology that otherwise
would have manifested as a late onset form. Again, the
depressive syndrome was resistant to antipsychotic/
antidepressant therapy at maximum dose, suggesting that
BGC may induce resistance to antidepressant treatment,
in addition to cognitive decline (cases 3–4), and head
trauma (case 4).
Case 5 presents a strio-pallido-dentate and occipital
calcinosis [3], probably of idiopathic origin (Fahr’s disease).
Despite a quite extensive calcification, symptoms were
really mild, and the diagnosis was incidental. At neu-
ropsychologic evaluation very mild cognitive deficits
emerged: this could represent the outset of a late onset
form, commonly characterized by dementia [46, 47],
even if vascular dementia could not be excluded. Finally,
BGC can be secondary to the small brain tumor [30, 31];
usually, gliomas and angiomas are involved, while no
association with meningiomas have been reported in
literature.
Case 6 presented a strio-pallidal calcinosis [3] prob-
ably secondary to hyperparathyroidism. On the opposite
of case 5, this patient initially had a mild-moderate burden
of calcification, but symptoms were quite severe from the
beginning. This late onset form was characterized by
progressively worsening cognitive deficits associated
with psychotic disturbances partially responsive to ther-
apy. Movement disorders were present from the begin-
ning and continued after suspension and change of
treatment. Cognitive impairment was attributable to
brain calcifications since it progressed to severe dementia
before the appearance of vascular lesions and atrophy.
Finally, case 7 presented a strio-pallido-dentate calcinosis
[3] probably due to secondary hyperparathyroidism. The
patient showed a late onset form with early cognitive and
motor dysfunction and later appearance of behavior dis-
turbances. The brain atrophy and the responsiveness of
behavioral disturbances to treatment may suggest the dis-
turbances were secondary to degenerative encephalopathy,
rather than to BGC. Another possibility is to consider the
brain atrophy itself as a consequence of BCG, as neurode-
generation has been reported to occur later in the course
of the disease in some cases [15, 51]. The hypertonia unre-
sponsive to L-dopa could be due to BGC or to cerebrovas-
cular disease, suggested by the anamnestic presence of
previous stroke.
The conclusions of our report are limited by the lack
of anatomical pathology studies evaluating the real burden
of calcification, and by the incomplete information we ob-
tained about some of our cases. However, Fahr’s disease is
a quite rare disorder, and by comparing 7 cases (one with
each other and with literature) we could suggest some
interesting conclusions:
1. Cognitive impairment
Even with a variable severity, it seems to be a constant
finding in patients with basal ganglia calcification; in
particular, the two domains most commonly involved in
our experience seem to be memory and attention. This
observation might result from the fact that basal ganglia
play a role in maintaining the integrity of cognitive func-
tions. Alternatively, the calcification of basal ganglia may
be a marker of other alterations related to cognitive im-
pairment, such as reduction of cerebral blood flow, atro-
phy, ischemic sub-cortical lesions. Anyway, our findings
strongly argue against the lack of cognitive symptoms in
these type of patients.
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2. Anxiety and depression
They are common in patients with basal ganglia calcifica-
tion, but less than the cognitive decline. In our experience,
depression in BGC is resistant to pharmacologic therapy.
Anxiety and depression might be secondary to the impair-
ment of the serotonin and dopamine pathways involved in
the limbic system. Depression, frequently associated to cog-
nitive impairment, might also represent a phenomenon
preceding the onset of dementia, as often happens in the
natural history of this disease [59].
3. Psychotic disorders
They may be associated to basal ganglia calcification.
When present, they are usually severe, with different grade
of structure and emotional involvement; nevertheless, we
didn’t observe a clear pattern of presentation of psychotic
symptoms (different organic background?). Moreover, in
agreement with literature, psychosis poorly responds to
specific treatment.
4. Extrapyramidal disorders
We observed only few cases (4/7) of extra pyramidal
disorders probably related to the disease; in particular,
significant gait disturbances and tremor were developed
by the three older individuals. Anyway, a mild extra pyr-
amidal syndrome might have developed also as a side
effect of antipsychotic drugs.
In conclusion, while Fahr's disease with early onset
seems to present fairly homogeneously, the clinical presen-
tation of late-onset forms of Idiopathic/Secondary BGC
seems to be much more heterogeneous, as evidenced by
the presented clinical cases and the data from literature.
Based on these results, we discourage the use of the
term “Fahr’s syndrome” to describe secondary causes,
and prefer referring to them as “Secondary Basal Ganglia
Calicification”.
Our data don’t allow to address the border phenotype
between physiological calcinosis and putative patho-
logical calcinosis of basal ganglia, since in our case series
all of seven cases present some pathological aspects.
This result might come from a “selection bias”: working
in a Clinic for the study of Cognitive Impairment, most
of the patients we evaluate come to our attention be-
cause of cognitive/behavioural/mood disturbances. How-
ever, we found basal ganglia calcifications in about 0.9 %
of our patients, and this result is not different from the
0.8 % found in the general population by Daghighi et al.
[8]. In our case series, basal ganglia calcification never
seems to be an isolated and clinically insignificant finding,
but always underlies cognitive/psychiatric/motor distur-
bances. Of consequence, although in some cases basal
ganglia calcification might be an occasional finding, some
cases (unknown percentage) present with overt clinical
symptoms, and the degree of calcification at neuroimaging
does not necessary correlate with the severity of clinical
picture. Of consequence, we suggest that all subjects with
the finding of BGC undergo a screening of cognitive per-
formance and mood state. It could be correct to consider
affected by “Fahr’s disease” only people in which BGC
have a pivotal role in determining the symptoms, while all
conditions in which calcifications are the marginal con-
sequence of different insults to basal ganglia should be
labelled as BGC.
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